111688 ⎘
ssRNA viruses positive-sense; Details; Togaviridae; Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki Demonstrated effect
METHODS FOR CASCADE AMPLIFICATIONS OF THERAPEUTIC PAYLOADS (CATP) & COMPOSITIONS FOR CANCER IMMUNOTHERAPIES AND GENE THERAPY
#2SELF-AMPLIFYING mRNA VACCINE BASED ON Z7 GENOME
#3TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
#4INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION
#5PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA
#6MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF
#7Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#8Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
#9Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
#10Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#11Alphavirus nsP mutants as vaccines
#12Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
#13Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
#14Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
#15Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
#16Rabies virus vaccine
#17Pegylated liposomes for delivery of immunogen-encoding RNA
#18Methods for in vitro evolution of constructs derived from viruses
#19Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#20Alphavirus NSP mutants as vaccines
#21Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
#22Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
#23Recombinant isfahan viral vectors
#24West Nile Virus vaccine
#25Engineered vesicles comprising antigenic peptides and the uses thereof as modulators of immune responses
#26CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP-REPLICON
#27Alkynyl-derivatized cap analogs, preparation and uses thereof
#28Method to kill pathogenic microbes in a patient
#29Virus like particle comprising modified envelope protein E3
#30TUMOR THERAPY WITH REPLICATION COMPETENT SINDBIS VIRAL VECTORS
#31Small liposomes for delivery of immunogen encoding RNA
#32Mucosal and Systemic Immunization with Alphavirus Replicon Particles
#33West Nile Virus vaccine
#34COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
#35Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
#36Tumor therapy with replication competent sindbis viral vectors
#37TUMOR THERAPY WITH NON-VIRAL-BASED HIGH AFFINITIY LAMININ RECEPTOR-TARGETED VECTORS
#38TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGETED VECTORS AND COMPOUNDS
#39TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGET VECTORS AND COMBINATIONS WITH CHEMOTHERAPEUTIC AGENTS
#40Tumor therapy with high affinity laminin receptor-targeted vectors